# Low-dose Interleukin-2 and Rapamycin on sjögren's Syndrome

> **NCT05605665** · PHASE1,PHASE2 · COMPLETED · sponsor: **Peking University People's Hospital** · enrollment: 30 (actual)

## Conditions studied

- Sjögren's Syndrome

## Interventions

- **DRUG:** low-dose interleukin-2
- **DRUG:** rapamycin

## Key facts

- **NCT ID:** NCT05605665
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-05
- **Primary completion:** 2023-12-30
- **Final completion:** 2024-03-31
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05605665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05605665, "Low-dose Interleukin-2 and Rapamycin on sjögren's Syndrome". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05605665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*